Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> BACKGROUND</h3><p>Although both PSA nadir (PSAn) and testosterone levels at PSA failure are known prognostic factors in men undergoing radiation therapy (RT) and androgen deprivation therapy (ADT) for unfavorable‐risk prostate cancer (PC), it is unclear whether their prognostic significance is independent or overlapping.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> METHODS</h3><p>Seventy‐five men treated with RT with or without 6 months of ADT for unfavorable‐risk nonmetastatic PC enrolled in 2 prospective clinical trials between 1986 and 2001 formed the study cohort. Competing risks and Cox multivariable regression were used to assess whether low versus normal serum testosterone at the time of PSA failure and higher PSAn after initial therapy were independently associated with the risk of PC‐specific (PCSM) and all‐cause mortality (ACM) adjusting for PC prognostic factors.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> RESULTS</h3><p>After a median follow‐up of 15.34 years (interquartile range, 6.66‐16.88 years), there were 53 deaths (73.3%): 30 (56.6%) were from PC. Low testosterone at PSA failure was significantly associated with an increased risk of PCSM (adjusted HR [AHR], 7.77; 95% CI, 1.14‐52.99; <i>P</i> = .04) and ACM (AHR, 3.01; 95% CI, 1.01‐8.96; <i>P</i> = .05), as was higher PSAn (PCSM AHR, 1.03; 95% CI, 1.01‐1.05; <i>P</i> < .01; ACM AHR, 1.04; 95% CI, 1.02‐1.07; <i>P</i> < .01), although the prognostic significance of PSAn was only noted in men with a normal testosterone at PSA failure. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> CONCLUSIONS</h3><p>Low testosterone level at PSA failure in high‐risk patients with PC treated with RT is associated with increased PCSM and ACM risk. In men with normal testosterone levels at the time of PSA failure, an elevated PSAn was associated with worse PCSM and ACM risk.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> LAY SUMMARY</h3><p>This study investigates whether the prostate‐specific antigen (PSA) nadir and normal versus low testosterone at the time of PSA failure provide mutually exclusive or overlapping prognostic information following treatment with radiation and androgen deprivation therapy for unfavorable‐risk patients with prostate cancer using data from 2 prospective clinical trials. It was found that both provided prognostic information; however, higher PSA nadir was only found to be of prognostic significance in men with normal testosterone levels at PSA failure.</p></section>

Primary study on the relationship of pre-therapy testosterone and prognositic factors of prostate adenocarcinoma

Relationship between prostate specific antigen new parameters and Gleason score and clinical stage

The relationship of BMI and pre-therapy testosterone with the prognositic factors of prostate adenocarcinoma

The relationship between serum testosterone and progression of advanced prostate cancer

Is there a relationship between testosterone and androgen receptor with prostatectomy outcomes?

Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer.

Low Serum Testosterone is Associated with Tumor Aggressiveness and Poor Prognosis in Prostate Cancer.

Lower pretreatment serum testosterone level predicts poor prognosis in the patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy

Low Serum Testosterone Predicts Upgrading and Upstaging of Prostate Cancer after Radical Prostatectomy

(076) Serum Testosterone Level As A Predictor Of Adverse Pathological Outcomes In Men With Prostate Cancer

Prostate-Specific Antigen Kinetics under Androgen Deprivation Therapy and Prostate Cancer Prognosis

Clinical Implications of Peripheral CD+3CD+69 T-Cell And CD+8CD+28 T-Cell Proportions in Patients Prior to Radical Prostatectomy

Pre-treatment circulating reproductive hormones levels predict pathological and survival outcomes in breast cancer submitted to neoadjuvant chemotherapy

A Possible Relationship Between Serum Sex Hormones and Benign Prostatic Hyperplasia/lower Urinary Tract Symptoms in Men Who Underwent Transurethral Prostate Resection

Analysis of Neoadjuvant Hormonal Deprivation for Prostatic Cancer Before Radical Prostatectomy

Platelet to Lymphocyte Ratio As an Independent Prognostic Indicator for Prostate Cancer Patients Receiving Androgen Deprivation Therapy.

Prostate‐specific antigen nadir and testosterone level at prostate‐specific antigen failure following radiation and androgen suppression therapy for unfavorable‐risk prostate cancer and the risk of all‐cause and prostate cancer–specific mortality

Research on the Association of Plasma TGF-β1 Level and Blood Lymphocyte/monocyte Ratio with Pathological Grade, Clinical Stage and Prognosis of Prostate Cancer.

Role of preoperative hormone therapy in localised prostate cancer:Meta-analysis based on six randomized controlled trials

Clinical Analysis on the Treatment of Prostate Cancer

Analysis of Risk Factors for Early Progression of Prostate Cancer After Initial Endocrine Therapy